hematopoietic stem cells Archives | Page 5 of 5

Cord Blood Scientific Publications May Predict What Will Happen in 2015 and Beyond

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

Trend rate data is valuable for understanding current industry conditions, as well as for predicting future behavior within the cord blood industry.

In upcoming posts, we will be presenting a range of valuable trend rate data, pulled from diverse sources, including grant funding databases, patent databases, clinical trial databases, and more.

In this post, we will begin with an analysis of scientific publication rate data for cord blood industry, because it is an important way to gauge innovation and progress within the marketplace.

Scientific Publication Rate Analysis

PubMed is a service of the U.S. National Library of Medicine and the National Institutes of Health (NIH) that contains citations from MEDLINE and a diverse collection of other life science journals. The data below was generated using the PubMed database, because it is the largest, most comprehensive, and most up-to-date global meta-database available for scientific publications.[1]

It is also the most versatile tool for screening by multiple criteria. [Read more…]

Advantages of Umbilical Cord Blood for Use in HSCT

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

The stem cells found in cord blood are largely hematopoietic stem cells, which can help in the replenishment of a depleted blood supply by providing new, healthy cells. In the case of certain diseases, such as leukemia, anemia, lymphoma, and others where the blood cells and tissues are severely affected, this replenishment is essential.

There are several important properties of cord blood, including that the number of hematopoietic stem cells in cord blood equals, or exceeds, the frequency of hematopoietic stem cells in bone marrow. In addition, cord blood hematopoietic stem cells can produce large colonies in vitro, have different growth factor requirements, and can be expanded in long-term culture.[1]

Also, cord blood stem cells are characterized as multipotent, because they are capable of differentiating into numerous stem cell types, including neurons, hepatic cells, and circulating cell types.[2]
[Read more…]

“Cord Blood” Reaches Nearly $40 Per Click in the U.S. and More Than $20 Per Click Worldwide

February 18, 2015 By Cade Hildreth (CEO) 1 Comment

Because Google controls over 70% of online searches, it is an incredible resource for analyzing online search behavior. Recently, the search term “Cord Blood” became one of the 20 most expensive keywords on Google Adwords,[1] an incredible finding given the variety and total volume of searches that occur through Google.

Individuals or companies who buy the exact search phrase “Cord Blood” through Google AdWords now pay $38.38[2] to win search traffic for this phrase within the United States. [Read more…]

Cord Blood Industry News Round-Up | February 2015

February 10, 2015 By Cade Hildreth (CEO) Leave a Comment

The cord blood banking industry is a rapidly evolving industry. Every month there are major events occurring in the sector that shift industry dynamics. Often, these events are announcements of technical or scientific advancements. Sometimes they are announcements of major industry alliances. Occasionally, they are announcements of a new industry competitor, a major milestone, or a significant funding award.

For those of us interested in the cord blood industry, tracking these shifting industry dynamics is of paramount importance. For this reason, this post covers the most significant cord blood industry news events as of February 2015.
[Read more…]

What Percentage of U.S. Parents Store Cord Blood Publicly and Privately?

February 8, 2015 By Cade Hildreth (CEO) Leave a Comment

The cord blood banking industry has grown increasingly complex over the past few years. While rates of growth within the industry were robust during the early 2000’s, it is no longer the rapid growth market that it used to be. There is now increased market competition, tighter regulatory standards, more substantial government oversight, and increased public scrutiny given toward cord blood industry practices.
[Read more…]

Scientific Publication Rate Analysis

BioInformant's World-Class Clients